Statin Therapy as a Preventive Strategy for Nephrolithiasis: A Review of Current Evidence

Recurrent nephrolithiasis remains a significant clinical challenge due to the highly variable and multifactorial etiology of kidney stone formation, which complicates the development of effective preventive strategies. Statins, or 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, are among the most widely prescribed medications, primarily for their cholesterol-lowering effects. Beyond their lipid-lowering properties, statins exhibit pleiotropic effects, including anti-inflammatory and antioxidative actions, that may contribute to reducing kidney stone formation. Moreover, statins are widely available, well-tolerated, and safe, highlighting them as a promising therapeutic option for nephrolithiasis prevention. Preclinical studies and observational data suggest that statins could play a role in preventing recurrent kidney stones. Despite encouraging preliminary findings, however, clinical evidence supporting the efficacy of statins in kidney stone prevention is currently limited. This review explores the potential mechanisms, preclinical findings, and current evidence regarding the use of statins as an adjunct therapy for recurrent nephrolithiasis and discusses the need for prospective clinical trials to investigate the efficacy of this therapy. .